期刊
INTERNATIONAL JOURNAL OF PHARMACEUTICS
卷 465, 期 1-2, 页码 175-186出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijpharm.2014.02.023
关键词
Nano carrier; Nano-transfersomes; Transdermal gel; Drug delivery; Stability; Toxicity
资金
- University Grants Commission, Government of India [32-136/2006]
- CSIR, India
The objective was to develop a stable, reproducible and patient non-infringing novel transdermal drug delivery system nano-carrier transdermal gel (NCTG) in combination of partial dose replacement of diclofenac diethylamine (DDEA) by curcumin (CRM). The drug content of gel was 99.30 and 97.57% for DDEA and CRM. Plasma samples were analyzed by liquid chromatography with triple-quadrupole tandem mass spectrometer (LC-MS/MS). Data were integrated with Analyst (TM) and analyzed by WinNonlin; stability parameters were analyzed using Tukey-Kramer multiple comparison test. Its average skin irritation scored 0.49 concluded to be non-irritant, safe for human use and in vivo studies revealed significantly greater extent of absorption and highly significant inhibition (%) of carrageenan induced paw edema. The results also demonstrated that encapsulation of drugs in nano-carrier increases its biological activity due to superior skin penetration potential. Hence, a novel once day transdermal gel of nano-carrier (nano-transfersomes; deformable vesicular) is achieved, to increase systemic availability, subsequent reduction in dose and toxicity of DDEA was developed for the treatment of inflammation. 2014 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据